Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Rezo Therapeutics

Request full access

Revolutionizing Drug Discovery by Mapping Biological Networks

San Francisco, United StatesFounded 2021Biotech & Life Sciences

About Rezo Therapeutics

Rezo Therapeutics, founded in 2021, is a biotechnology firm centered on mapping disease networks to develop precision medicines. The company officially launched in November 2022, securing $78 million in a Series A financing round led by SR One, a16z Bio + Health, and Norwest Venture Partners. This initial funding was aimed at expanding operations and advancing the company's development efforts.

The company's scientific foundation is built upon technology developed at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF). The co-founding team comprises a distinguished group of UCSF scientists and seasoned biotech executives, including Nevan Krogan, Ph.D., Kevan Shokat, Ph.D., Sourav Bandyopadhyay, Ph.D., Natalia Jura, Ph.D., George Scangos, Ph.D., and Norbert Bischofberger, Ph.D. Dr. Krogan, who is also the director of QBI, initially served as the company's CEO and now holds the position of President. His academic work, which combines genetics with molecular and systems biology, is central to Rezo's approach. In August 2025, Derek Hicks, a veteran with over 25 years of experience at firms like Intellia Therapeutics, Spark Therapeutics, and Pfizer, was appointed CEO to guide the company's next growth phase.

Rezo's core is its proprietary "Sequence to Systems to Drugs" (SSD) platform. This platform integrates multiple complex disciplines, including proteomics, genetics, structural biology, chemistry, and bioinformatics, to construct comprehensive maps of molecular disease networks. By analyzing the intricate web of protein-protein, genetic, and biochemical interactions that drive diseases, the SSD platform aims to identify novel, druggable targets that are often missed by traditional, more siloed drug discovery methods. This approach allows for the discovery of tumor-specific vulnerabilities and the development of precision therapies. The business model revolves around leveraging this platform to build a pipeline of therapeutics, initially focusing on solid tumor oncology, with intentions to explore other therapeutic areas through strategic partnerships and collaborations.

Source: Dealroom company data

At a glance

Status
Operational
Employees
44
Open positions
4
Dealroom signal
77.6/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Nov 2022 $78M $312M SV Angel · Hawktail · Andreessen Horowitz · Norwest Venture Partners ↗
SPINOUTOther financing Jan 2021 $0 — University of California, San Francisco —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Rezo Therapeutics website traffic

Latest recorded traffic for Rezo Therapeutics is 5.5K monthly website visits, up 139.1% over the last three months. Rezo Therapeutics's team grew 15.8% over the past year.

Latest monthly visits5.5K 3-month web change+139.1% 1-year team growth+15.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Rezo Therapeutics in the San Francisco ecosystem

Live from Dealroom

The Rezo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Other known investors1 additional known investor

  • University of California, San Francisco
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States96.4%
🇮🇹 Italy3.6%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Rezo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rezo Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.